Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for healthcare industry professionals · Friday, March 29, 2024 · 699,691,129 Articles · 3+ Million Readers

Global Psoriatic Arthritis Market 2017-2035 - Biosimilar TNF-Alpha Inhibitors Present the Greatest Challenge to Wider Uptake of Cosentyx and Taltz

Dublin, June 24, 2019 (GLOBE NEWSWIRE) -- The "Psoriatic Arthritis Market and Forecast Analysis 2035" report has been added to ResearchAndMarkets.com's offering.

Psoriatic arthritis (PsA) is an inflammatory arthropathy associated with psoriasis, which is classified within the group of spondyloarthritis. With the exception of the distal interphalangeal joints (hands and feet), there are no predictable joints for involvement in PsA, and the signs of inflammation are often more difficult to detect than those associated with rheumatoid arthritis. PsA is common in patients with psoriasis, and there is some evidence to suggest that the severity of psoriasis is associated with an increased risk for - although not greater severity of - PsA.

Market Snapshot

  • Cosentyx will displace Stelara as the preferred biologic in the post-TNF setting.
  • Humira is the preferred biologic to treat PsA due to its efficacy in skin and joint symptoms.
  • A modest 6.8% increase in the diagnosed prevalent population of psoriatic arthritis is forecasted during 2017-37.
  • The increasing availability of novel biologic therapies is set to intensify competition in the post-TNF setting.
  • Product differentiation is critical for new biologic and small molecule therapies attempting to enter the market.
  • Biosimilar TNF-alpha inhibitors present the greatest challenge to wider uptake of Cosentyx and Taltz.

Key Topics Covered:

FORECAST: PSORIATIC ARTHRITIS (Published on 16 October 2017)
Overview
Executive Summary
Market Overview And Trends
Market Definition And Methodology
Cimzia (Certolizumab Pegol)
Cosentyx (Secukinumab)
Enbrel (Etanercept)
Humira (Adalimumab)
Orencia (Abatacept)
Otezla (Apremilast)
Remicade (Infliximab)
Simponi (Golimumab)
Stelara (Ustekinumab)
Taltz (Ixekizumab)
Tremfya (Guselkumab)
Xeljanz (Tofacitinib)

TREATMENT: PSORIATIC ARTHRITIS (Published on 16 October 2017)
Overview
Executive Summary
Primary Research Methodology
Disease Definition And Diagnosis
Patient Segmentation
Current Treatment Options
Prescribing Trends
Compliance
Unmet Needs In Psoriatic Arthritis
Future Treatment Trends
Impact Of Biosimilars

EPIDEMIOLOGY: PSORIATIC ARTHRITIS (Published on 24 July 2018)
Overview
Disease Background
Methodology
Forecast
Bibliography
Appendix: Additional Sources

MARKETED DRUGS: PSORIATIC ARTHRITIS (Published on 17 October 2017)
Overview
Executive Summary
Product Overview
Product Profile: Cimzia
Product Profile: Cosentyx
Product Profile: Enbrel
Product Profile: Humira
Product Profile: Orencia
Product Profile: Otezla
Product Profile: Remicade
Product Profile: Siliq
Product Profile: Simponi
Product Profile: Stelara
Product Profile: Taltz

PSORIATIC ARTHRITIS PRICING, REIMBURSEMENT, AND ACCESS (Published on 24 June 2016)
Overview
Executive Summary
Market Context
Global Payer Insights
Us Pricing
Us Payer Insights
Us Reimbursement
Japan
Five Major Eu Markets Pricing
Five Major Eu Markets Payer Insights
Biosimilar Tnf-Alpha Inhibitors In The Five Major Eu Markets
France
Germany
Italy
Spain
Uk
Methodology

PIPELINE: PSORIATIC ARTHRITIS (Published on 17 October 2017)
Overview
Executive Summary
Clinical Pipeline Overview
Additional Pharma Intelligence Pipeline Resources
Product Profile (Late Stage): Tremfya
Product Profile (Late Stage): Xeljanz
Product Profile (Late Stage): Upadacitinib

For more information about this report visit https://www.researchandmarkets.com/r/scbyh5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

                    CONTACT: ResearchAndMarkets.com
                             Laura Wood, Senior Press Manager
                             press@researchandmarkets.com
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                    Related Topics: Immune Disorders Drugs, Musculoskeletal Disorders Drugs
                    

22157.jpg

Powered by EIN News


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release